How to avoid harm with feeding critically ill patients: a synthesis of viewpoints of a basic scientist, dietitian and intensivist

A Reintam Blaser, O Rooyackers, DE Bear - Critical Care, 2023 - Springer
The optimal feeding strategy in critically ill patients is a matter of debate, with current
guidelines recommending different strategies regarding energy and protein targets. Several …

Triglyceride-glucose index linked to all-cause mortality in critically ill patients: a cohort of 3026 patients

Y Liao, R Zhang, S Shi, Y Zhao, Y He, L Liao… - Cardiovascular …, 2022 - Springer
Abstract Background Triglyceride-glucose (TyG) index as a reliable surrogate of insulin
resistance (IR) has been shown to be related to adverse clinical outcomes in patients with …

[HTML][HTML] Model-based subcutaneous insulin for glycemic control of pre-term infants in the neonatal intensive care unit

T Zhou, M Boettger, JL Knopp, M Lange, A Heep… - Computers in Biology …, 2023 - Elsevier
Hyperglycaemia is a common problem in neonatal intensive care units (NICUs). Achieving
good control can result in better outcomes for patients. However, good control is difficult …

Is the DISST applicable to a Malaysian cohort?

MH Abbas, SA Shamsuddin, NA Othman… - … on Control, Decision …, 2023 - ieeexplore.ieee.org
The dynamic insulin sensitivity and secretion test (DISST) is a dynamic test that can quantify
participant-specific insulin sensitivity (SI) values and endogenous insulin (U_N) profiles. It is …

Model-Based Glycaemic Control in Critically Ill Diabetes Mellitus Patients: Monte Carlo Sensitivity Analysis

AA Razak, NN Razak, N Nor Hisham Shah… - Proceedings of the 12th …, 2022 - dl.acm.org
Insulin resistance and sensitivity variabilities exacerbated diabetes mellitus (DM) and non-
diabetes mellitus (NDM) patients' conditions in the intensive care unit (ICU). This problem …

[PDF][PDF] Modelling endogenous glucose production and glucose uptake in human health and disease

J Ormsbee - 2022 - ir.canterbury.ac.nz
Diabetes is a world-wide problem with epidemically increasing prevalence. By 2040, more
than 10% of adults world-wide will have diabetes and it is estimated to cost US $2.1 trillion …